Mirati Therapeutics Inc. (MRTX)
NASDAQ: MRTX
· Real-Time Price · USD
58.70
-0.10 (-0.17%)
At close: Jan 22, 2024, 10:00 PM
Mirati Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 38.19M | 27.22M | 18.89M | 12.44M | 11.8M | 78.16M | 72.8M | 72.09M | 73.5M | 13.13M | 13.13M |
Cost of Revenue | 145.62M | 275.01M | 402.07M | 532.23M | 544.23M | 529.26M | 535.5M | 508.59M | 437.46M | 401.2M | 331.71M |
Gross Profit | -108.29M | -247.79M | -383.17M | -519.79M | -532.43M | -451.1M | -462.7M | -436.5M | -363.96M | -388.07M | -318.58M |
Operating Income | -764.87M | -779.26M | -769.19M | -759.59M | -744.94M | -638M | -624.98M | -573.18M | -482.44M | -491.62M | -412.3M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -725.62M | -737.03M | -736.56M | -740.36M | -737.76M | -641.21M | -631.19M | -578.49M | -479.95M | -490.53M | -406.96M |
Net Income | -725.88M | -737.53M | -737.07M | -740.87M | -738.54M | -645.03M | -635.02M | -582.31M | -483.95M | -492.06M | -406.91M |
Selling & General & Admin | 291.8M | 280.6M | 259.34M | 239.8M | 212.51M | 186.9M | 162.28M | 136.68M | 118.48M | 103.55M | 93.72M |
Research & Development | 506.87M | 523.18M | 527.33M | 531.63M | 544.23M | 529.26M | 535.5M | 508.59M | 437.46M | 401.2M | 331.71M |
Other Expenses | 1.38M | 14.25M | 14.76M | 10.33M | 7.18M | -3.21M | -6.21M | -5.3M | 2.49M | 1.09M | 5.33M |
Operating Expenses | 798.93M | 803.78M | 786.67M | 771.42M | 756.74M | 716.16M | 697.78M | 645.27M | 555.94M | 423.56M | 277.15M |
Interest Expense | n/a | n/a | n/a | 4.17M | 4.17M | 4.17M | 4.17M | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | -98.16M | -98.16M | -98.16M | -98.16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 803.06M | 806.48M | 788.09M | 772.02M | 756.74M | 716.16M | 697.78M | 645.27M | 555.94M | 504.75M | 425.43M |
Income Tax Expense | -10.1M | -8.73M | -8.58M | 4.83M | 4.71M | 7.75M | 7.46M | 3.29M | 3.72M | 1.25M | -182K |
Shares Outstanding (Basic) | 64.99M | 58.23M | 58.03M | 57.67M | 56.22M | 55.55M | 55.41M | 53.62M | 51.66M | 51.47M | 50.78M |
Shares Outstanding (Diluted) | 64.99M | 58.23M | 58.03M | 57.67M | 56.22M | 55.55M | 55.47M | 53.62M | 51.66M | 51.47M | 50.78M |
EPS (Basic) | -12.06 | -12.66 | -12.8 | -13.26 | -13.48 | -11.94 | -11.99 | -11.18 | -9.54 | -9.97 | -8.59 |
EPS (Diluted) | -12.06 | -12.66 | -12.8 | -13.25 | -13.47 | -11.93 | -11.98 | -11.18 | -9.54 | -9.97 | -8.59 |
EBITDA | -760.68M | -775.47M | -765.82M | -756.66M | -742.9M | -636.16M | -623.42M | -571.96M | -481.22M | -490.73M | -411.69M |
EBIT | -755.41M | -769.8M | -759.74M | -756.28M | -744.94M | -638M | -624.98M | -573.18M | -482.44M | -491.62M | -412.3M |
Depreciation & Amortization | 4.19M | 3.79M | 3.38M | 2.93M | 2.6M | 2.4M | 2.12M | 1.78M | 1.43M | 1.09M | 809K |